GFP Adeno-Associated Virus ( AAV-Kera1 )

Vectors based on adeno-associated viruses (AAV) have emerged as one of the most promising delivery systems for clinical applications. They have low immunogenicity, can be produced at very high titers and deliver DNA vector genomes that form episomes that serve as transcriptional templates. The prototypical AAV vector is based on serotype 2 (AAV2). It can be pseudotyped with capsids from other natural serotypes or engineered capsids. This vector has been reported to be useful for treating a range of genetic diseases, such as hemophilia B, Leber's congenital amaurosis or lipoprotein lipase deficiency. However, the use of this vector system for the treatment of genetic skin diseases or wound healing disorders has been hampered by the fact that primary human keratinocytes (HK) are resistant to AAV-mediated transduction. GFP AAV-Kera1 is a breakthrough tool in gene therapy specifically designed to target keratinocytes with high precision. This recombinant AAV (rAAV) is uniquely engineered with a capsid derived from AAV serotype 2 (AAV2). The engineered capsid with the RGDTATL peptide inserted and the addition of a GFP reporter gene make it a valuable vector for research and therapeutic purposes. As advances in genetic engineering continue, AAV-Kera1 demonstrates the potential for customized viral vectors to revolutionize the treatment of a variety of skin diseases and other conditions.